Authors Jie Xiong , Yu-Ting Dai , Wen-Fang Wang , Hao Zhang , Chao-Fu Wang , Tong Yin , Shu Cheng , Hui-Juan Zhong , Shan-He Yu , Lu Jiang , Sheng-Yue Wang , Hai Fang , Rui-Hong Zhang , Yue Zhu , Hong-Mei Yi ,

While a chemistry undergraduate student at the University of Chicago, he attended a NATO Advanced Study Institute in Les Houches, France in 1979 where he was exposed for the first time to the nascent field Gobind Khorana at the Department of Chemistry at M.I.T. for postdoctoral training, where he learned gene He also went on to discover a “counterion switch” in visual pigments and to develop strategies to assay Recently, Tom’s lab discovered, along with Yu Chen and Ping Chi , that a mutant of CYSLTR2 is a driver

For postdoctoral training, he joined the laboratory of Dr. Strosberg AD in France, where he worked on the regulation of ß-adrenergic receptors. He is the Research director at INSERM with a specific interest in G protein-coupled receptors by developing He showed the formation of melatonin receptor heteromers in vitro and in vivo and their importance in He is a highly cited researcher – 2019 and 2020 identified by Clarivate Web of Science ™. Dr.

HE staining, ELISA, and immunohistochemistry were used to evaluate pathological changes and the degree Authors Juan Song , Miao Li , Cuicui Chen , Jian Zhou , Linlin Wang , Yu Yan , Jun She , Lin Tong , Yuanlin

He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. He did his postdoctoral training with Dr. Marc G. He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of He was a recipient of Canada's Top 40 under 40 award in 2004 and received Queen Elizabeth II, Diamond Most recently, in 2021, he was elected as a Fellow of the Canadian Academy of Health Science (FCAHS).

He earned his master's degree in biotechnology from Jawaharlal Nehru University in India and it was during a biochemistry class where he learned about cell signaling that he became curious and wanted to learn working on GPCRs and their structural characterization at the Max Planck Institute of Biophysics where he Fascinated by GPCRs he wrote to Dr. Bob Lefkowitz and asked him if he could join his lab at Duke University. Dr.

He also directs a collaborative neuroscience R&D program with Servier (France) and is the co-founder company (2009-2012), where he was responsible all of the company’s discovery biology. He is an acknowledged expert in drug discovery, particularly in the field of psychiatry, where he has He has a degree and PhD in pharmacology from Queens' College, Cambridge and University College London He is also a corresponding member of NC-IUPHAR.

He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. He did his postdoctoral training with Dr. Marc G. He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of He was a recipient of Canada's Top 40 under 40 award in 2004 and received Queen Elizabeth II, Diamond Most recently, in 2021, he was elected as a Fellow of the Canadian Academy of Health Science (FCAHS).

Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions In addition, he is a member of the board of directors of the San Diego Entrepreneurs Exchange, a nonprofit organization that provides resources for early-stage start-ups, which he co-founded in [2009.]

David Gloriam is a Professor in Computational Receptor Biology at the University of Copenhagen where he He later identified physiological hormones of such under characterized ‘orphan’ receptors and functional He completed two postdocs in the UK at the EMBL-European Bioinformatics Institute and GlaxoSmithKline In 2018 he joined the University of Copenhagen, where he has received an ERC Starting Grant, Lundbeck He is one of the coordinators of recommendations to describe ligand bias towards signaling probes and

He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis In 2015, He joined Dr. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards

He subsequently enrolled in the Medical Scientist Training Program at The University of Chicago. Keith Moffat, he studied the structural mechanisms of bacterial photoreceptors using time-resolved Laue He was awarded his Ph.D. in 2004 and his MD in 2006. He then joined the Internal Medicine Residency training program at Duke University Medical Center. During his Cardiology fellowship, he trained in the lab of Dr. Robert J.

regulating the exosomal proteome and demonstrate its ability to promote cancer cell motility. " Authors Yu Jin Lee , Kyeong Jin Shin , Hyun-Jun Jang , Jin-Sun Ryu , Chae Young Lee , Jong Hyuk Yoon , Jeong Kon Park , Semin Lee , A Reum Je , Yang Hoon Huh , Sun-Young Kong , Taejoon Kwon , Pann-Ghill Suh , Young Chan

Timo De Groof studied Biochemistry and Biotechnology at the University of Ghent where he graduated in During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry From 2015 to 2019, he completed his Ph.D. in the Medicinal Chemistry group at VU University Amsterdam He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA Moreover, he is closely involved in multiple projects where he focuses on the generation of nanobodies

He obtained his B.S. in Chemistry from The University of Chicago in 1998 and subsequently enrolled in Keith Moffat, he studied the structural mechanisms of bacterial photoreceptors using time-resolved Laue He was awarded his PhD in 2004 and his MD in 2006. He then joined the Internal Medicine Residency training program at Duke University Medical Center. During his Cardiology fellowship, he trained in the lab of Dr. Robert J.

He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis In 2015, He joined Dr. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards

., he retired at the end of 2014 and since then has been writing papers on his final major project at Louis, followed by a Ph.D. in Neurosciences at the University of California, San Diego. During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab. He taught himself chemoinformatics as a way to optimize compound selection for screening, and in 1997

Liberal Arts from Reed College in 1976 and his Ph.D. in Chemistry from the University of California, San He completed postdoctoral training at the Weizmann Institute. In 1983, he joined the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the He is currently the Senior Investigator and Chief of the Molecular Recognition Section, Laboratory of He has published more than 800 scientific publications, with an H-index of 115.

He received his B.S. in Chemistry from Duke University in 2016 where he worked in the lab of Dr. He is currently finishing his Ph.D. in the lab of Dr. He primarily studies the chemokine receptor CXCR3 as it has three naturally occurring ligands and thus He hopes to continue his research on biased agonism at GPCRs with a particular focus on the treatment

Louis University in 1983, he subsequently trained in pharmacology (NIH), molecular biology, and psychiatry attending the lecture of a visiting professor on neurotransmission while in college in Montana, where he He was determined to work on psychiatric disorders and persevered even when he was told several times he would never make it as a basic scientist and would never publish anything important.

., 2012 Nobel Prize in Chemistry, which he shared with Dr. Brian Kobilka . Before we pressed record, I asked if I could call him Bob, and he answered that only his mom used to then pressed record, and we chatted for almost 2h about Bob’s career, discoveries, difficulties (yes, he ’s had some too), Nobel week, and his memoir that he just published in collaboration with Dr. His legacy lies in the numerous discoveries he and his team made in the GPCR field and in all those who

He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility He currently leads a team that provides a mechanistic understanding of small molecule drug candidates Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular He continues to pioneer in drug discovery studying GPCRs and other target classes.

He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility He currently leads a team that provides a mechanistic understanding of small molecule drug candidates Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular He continues to pioneer in drug discovery studying GPCRs and other target classes.

He is passionate about developing more rational ways to understand and engineer biology. Sri previously worked at the Wyss Institute and Harvard, where he built numerous technologies in gene He helped build Gen9, a gene synthesis company, as a member of the SAB and was the first employee of He is a Searle Scholar (2015), NIH New Innovator (2014), and received his ScD in Biological Engineering He enjoys eating, getting outdoors, and traveling with his wife and two children. Dr.

Instead, he ended up getting interested in membrane protein as he followed the biology of a bacterial Today he and his team are working on understanding receptor signaling in specialized cellular environments With over 2000 followers on Facebook and Twitter, he shares the latest available information on GPCR

He works in a multidisciplinary Chemical Biology team based at the recently established US R&D hub in He then moved to Denmark, where he trained at the University of Copenhagen under supervision of Professor He is an avid proponent of close collaboration between industry and academia." Dr. rather than taking specific courses. where he could immediately contribute due to his technical skills.

He is a first-generation college graduate and academic. After spending two years at the Cleveland Institute of Art, he earned degrees in Biochemistry and Chemistry He then went on to earn a Ph.D. in Molecular Biophysics from Johns Hopkins University, followed by postdocs Cellular Pharmacology Department at the University of Miami Miller School of Medicine in 2016, where he

He received his Ph.D. from the Centre for Cellular and Molecular Biology at Hyderabad, India, where he In addition, he explored the role of the host membrane in the entry of intracellular pathogens into macrophages He currently uses high-resolution fluorescence microscopy and biochemistry to study GPCR trafficking